Page 15 - hypertension_newsletter_Special_Servier_final

REFLECTIONS
Hypertension
Hypertension Special Edition – ESH 2024 Highlights

ADDITIONAL ABSTRACTS OF INTEREST Hypertension

EPIDEMIOLOGY

1. Intensive BP control for the prevention of cardiovascular events among individuals with hypertension at low
cardiovascular risk: a target trial emulated using observational data. Douros A, et al. J. Hypertens. 2024;42(Suppl 1):e25.

2. A European survey to identify current practices on the treatment of hypertension in adults >75 years in esh excellence
centres. Camafort M, et al. J. Hypertens. 2024;42(Suppl 1):e42.

METABOLIC COMORBIDITIES AND RISK FACTORS

3. Blood pressure variability and target organ damage indices in patients with Type 2 diabetes mellitus. Zarifis I, et al. J.
Hypertens. 2024;42(Suppl 1):e19.

4. Association of clinic and ambulatory blood pressure with mortality in patients with and without diabetes. Lauder L, et
al. J. Hypertens. 2024;42(Suppl 1):e9.

5. Peak nocturnal home blood pressure as an early and strong novel risk factor for stroke: The practitioner-based
nationwide J-HOP nocturnal BP study. Kario K, et al. J. Hypertens. 2024;42(Suppl 1):e9-e10.

6. Home blood pressure during night-time sleep as a better treatment target for patients with hypertension: A proof-of-
concept randomized controlled trial. Kam-Pui Lee E, et al. J. Hypertens. 2024;42(Suppl 1):e14.

7. Predictive factors for achievement of target systolic blood pressure and heart rate: Sub-analysis of PRIDE study.
Khomitskaya Y, et al. J. Hypertens. 2024;42(Suppl 1):e244.
8. Vascular age as a key for a team-based approach to manage blood pressure and cardiovascular risk between
community pharmacists and primary health care centers (TOGETHER). Rodilla E, et al. J. Hypertens.
2024;42(Suppl 1):e71.

TREATMENT

9. SYNERGIA -Morocco: effectiveness of hypertension management with an amlodipine and perindopril arginine-based
strategy in Morocco: Study design and preliminary data. El Khayat SS, et al. J. Hypertens. 2024;42(Suppl 1):e13.

10. Antihypertensive treatment of masked hypertension guided by ambulatory blood pressure monitoring: A double-
blind, placebo-controlled trial. Huang JF, et al. J. Hypertens. 2024;42(Suppl 1):e14.

11. Counteracting angiotensinogen small interfering RNA-mediated antihypertensive effects with Reversir. Cruz López E,
et al. J. Hypertens. 2024;42(Suppl 1):e45.

RESISTANT HYPERTENSION

12. Blood pressure control with aprocitentan in resistant hypertension. Narkiewica K, et al. J. Hypertens.
2024;42(Suppl 1):e12.

13. Chemical adherence in resistant hypertension: pilot study in an ESH excellence center. Sautenet B, et al. J. Hypertens.
2024;42(Suppl 1):e1.

14. Effect of sequential nephron blockade x dual renin-angiotensin system blockade +bisoprolol in the treatment of
resistant hypertension, a randomized controlled trial (RESHYPOT). Cestari EDE, et al. J. Hypertens.
2024;42(Suppl 1):e47-e48.

TABLE OF CONTENTS